A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects With Advanced Renal Cell Carcinoma.
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2015
At a glance
- Drugs AGS 16C3F (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; First in man; Pharmacokinetics
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 14 May 2015 Results will be presented at ASCO Annual Meeting 2015, per Astellas Pharma media release.
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.